Investor Notes - Phillip Securities (HK) Ltd
Past Investor Notes  
Phillip Home Send to Friends Free Subscription Give Comments 中文版
8 Dec, 2022 (Thursday)

            
MEDBOT(2252)
Analysis:
Shanghai MicroPort MedBot (2252) is primarily engaged in the development, manufacture and commercialisation of surgical robots. It is the only global surgical robot company with a product portfolio covering the five major and fast-growing surgical specialties of laparoscopic, orthopedic, panvascular, natural orifice and percutaneous surgical procedures, and has more than 10 products at the fast promotion stage of industrialization projects. The Group recently announced that the SkyWalker Total Knee System (registered name in China of which is Honghu), which is independently developed by the Group, has successfully obtained the CE Mark in Europe, becoming the first joint replacement surgical robot in China with the CE Mark in Europe. Also, Honghu is currently the first and only domestic surgical robot that has obtained the approval from the National Medical Products Administration (the NMPA), the clearance from the U.S. Food and Drug Administration (the FDA) and the CE Mark. Obtaining the CE Mark for Honghu embarks the first step for the Group to enter the European Union market. (I do not hold the above stock)
Strategy:
Buy-in Price: $33.50, Target Price: $36.50, Cut Loss Price: $32.00


SIHUAN PHARM(460)
Analysis:
For the six months ended 30 June 2022, Sihuan Pharmaceutical (00460) recorded revenue of RMB1,464.2 million, representing YoY decrease of 23.2%, mainly due to the impact of the continued development of the domestic epidemic and policy changes of the pharmaceutical industry in the first half of the year. The profit attributable to owners of the company was approximately RMB40.4 million, representing YoY decrease of 93.4%. The medical aesthetic business segment achieved a revenue of RMB98.6 million, representing a YoY decrease of 61.8%, mainly attributed to the decrease in consumptions caused by the inability to operate and provide service in downstream end due to the impact of the epidemic, and the impact has spread to the upstream of the industry chain resulting in less product supply. Company has continued to focus on the two major business segments of medical aesthetics and biopharmaceuticals to further upgrade its corporate value in 2022 based on the high growth in 2021. As the “star” business of the company, MeiYan KongJian, a medical aesthetics platform, will accelerate the upgrading and development of 2.0 version for marketing and sales, strengthen its capacity as an international medical aesthetics platform integrated with R&D, production and sales, and with a full product matrix covering the life cycle of beauty seekers. Through continuous implementation of the two-wheel drive strategy of “medical aesthetics + biopharmaceuticals” with high efficiency, Sihuan Pharmaceutical would promote the further release of corporate value.
Strategy:
Buy-in Price: $0.87, Target Price: $1.00, Cut Loss Price: $0.81



GWM (2333.HK) - New Energy Layout Is Accelerating

Investment Summary

With a Slight Improvement in the Overall Sales Volume in October, the Product Sales Structure Is Continued to Be Upgraded

Great Wall Motors reported a sales volume of 100.2 thousand units in October, down 11% yoy and up 7% mom. The year-on-year decline was mainly due to the disruption of demand of major automobile consuming provinces amid the spread of the pandemic in multiple places. However, Great Wall Motors displayed outstanding performance in the overseas sales in October. A total of 21,052 units were delivered, up 50% yoy and up 12% mom, accounting for 21% of the total sale volume. From January to October, Great Wall Motors` cumulative sales volume reached 903 thousand units, down 9.4% yoy. In particular, 107,870 new energy vehicles were sold accumulatively, up 9.95% yoy, accounting for 11.9% of the total sales volume. The proportion of the Company's high-value models continued to increase. From January to October 2022, Great Wall Motors` sales volume of models above RMB200 thousand accounted for 14.62%, up 4.93 ppts yoy; the sales volume of intelligent models accounted for 85.84%, up 10.54 ppts yoy; and the sales volume of the models of three major technology brands accounted for 70.56%, up 11.67 ppts yoy.

Haval and Tank Accelerate the Launch of New Energy Layout

In terms of sub-brands, Haval sold 63,759 units, up 1.9% yoy and up 18.2% mom, of which the sale volume of the main model Haval H6 was 35,127 units, up 28.5% yoy. In August, Haval announced its new energy strategy, accelerating its transition to the new energy track in a comprehensive manner, and plans to increase the sales proportion of new energy vehicles to 80% by 2025 and stop selling the traditional fuel-powered vehicles by 2030. At the end of September, the 3rd Gen Haval H6 DHT-PHEV was officially launched, which shows the stimulating effect on the total sales volume of Haval models. Haval is expected to launch a total of seven new energy models in two categories by the end of next year, including five plug-in hybrid electric models and two hybrid electric models. In the fourth quarter of this year, two new energy models, namely, the Shenshou PHEV and the Big Dog PHEV, will be launched. Haval is comprehensively accelerating the new energy layout.

Tank reported a sales volume of 12,753 units, up 28.2% yoy and up 1.1% mom. The average price of the Tank 300 and the Tank 500 exceeded RMB200 thousand and RMB300 thousand, respectively, which fully establishes the Company's ability to mine the characteristic segment. In the future, in addition to increasingly enriching the co-creation versions of existing models, new models such as the Tank 400, 700 and 800 will be launched in succession. At the previous Chengdu Motor Show, Tank showed the Tank 300 HEV and the Tank 500 PHEV, which are expected to be launched by the end of the year. Tank is also promoting the new energy layout.

Ora and Wey Are Still in the Transition Period

Ora delivered 5,572 units, down 57.9% yoy and down 26.7% mom. The decline was mainly affected by the discontinuation of low-priced models such as the Good Cat and the White Cat, reflecting that the brand is still in the transition period. On October 31, the new model Lightning Cat, which is positioned as a "super streamlined pure electric coupe", was officially launched. Within 24 hours of its launch, the large orders of the new model reached 15,305 units. The market layout has achieved initial results. It is expected to be a hot-selling model in the future. In terms of product planning, Ora will also launch multiple models such as the Punk Cat and the Cherry Cat in the future.

Wey reported a sales volume of 2,427 units, down 58.5% yoy and up 3.1% mom, reflecting the fierce market competition in the high-end models of self-own brands. In the future, Wey will make breakthroughs in the diversity of models. Retro SUV model "Yuan Meng", large six-seat SUV and MPV models, and sedan model are expected to be launched in succession. The product matrix will be encrypted to facilitate the sales rally.

GWM Pickup delivered 15,697 units, down 23.2% yoy and down 8.3% mom, of which the GWM Poer delivered 10,155 units, down 19.8% yoy and down16.1% mom. The sales volume has exceeded 10 thousand units for 27 consecutive months.

Investment Thesis

In 2022, due to the disruption resulting from the pandemic, the Company's original strong product cycle has been delayed. However, with the gradual disappearance of the negative factors, the recovery of capacity utilisation and the launch of a series of new models are expected to bring elasticity to the revenue and net profit. We think that Great Wall Motors` long-term layout of new technologies and new product systems will facilitate its share rally and bring stable returns in the future.

Considering revised financial forecast, we raised our target price to HK$14.1, equivalent to 11.8/12/8.8 x P/E in 2022/2023/2024. We gave the rating of “Buy”. (Closing price as at 5 December)

Risk

New vehicle sales fall short of expectations

The SUV market dramatically worsens

The progress of new energy vehicle/Pickup is poorer than expectations

Financials

Click Here for PDF format...




Recommendation on 8-12-2022
RecommendationBUY
Price on Recommendation Date$ 11.020
Suggested purchase priceN/A
Target Price$ 14.100
Writer Info
Zhang Jing
(Research Analyst)
Tel: (+86 21 51699400-103)
Email:
zhangjing@phillip.com.cn

Local Index
       Index    Change   Change%

World Index
       Index    Change   Change%
  

A-H spread
Stock Code H share
Price
A share
Price
H share
discount


Oversea Research Reports


Investment Service Centre



Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.

版權所有, 翻印必究。

Copyright(C) 2022 Phillip Securities (HK) Ltd. All Rights Reserved.